对galsulfase的现实世界药监分析:基于FDA不良事件报告系统 (FAERS) 数据库的研究
Shangze Li1, Runcheng Huang2, Yuanyuan Meng3
1Department of Orthopedics, The Second Affiliated Hospital (Changzheng Hospital), Naval Medical University, Shanghai, China.
Frontiers in pharmacology
|August 20, 2024
概括
这项研究分析了对VI型粘多糖症 (MPS VI) 的galsulfase (Naglazyme) 的真实数据,揭示了问题等新的不良事件. 持续的安全监测对于有效的酶替代疗法 (ERT) 是至关重要的.
科学领域:
- 药监和药物安全 药监和药物安全
- 溶酶体储存障碍 溶酶体储存障碍
- 酶替代疗法是一种酶替代疗法.
背景情况:
- 粘多糖症VI型 (MPS VI) 是一种由GAG积累引起的溶酶体储存障碍.
- 硫 (Naglazyme) 是MPS VI的关键酶替代疗法 (ERT).
- 对galsulfase的真实安全数据和不良事件 (AE) 需要全面分析.
研究的目的:
- 分析FDA不良事件报告系统 (FAERS) 数据库的galsulfase安全性.
- 在现实环境中识别与galsulfase相关的潜在风险和不良反应.
- 评估galsulfase治疗的安全性,并确定新出现的不良事件.
主要方法:
- 从FAERS数据库 (2005年第二季度 - 2023年第四季度) 提取数据,分析了3,195份与galsulfase相关的AE报告.
- 采用了四种算法 (ROR,PRR,BCPNN,MGPS) 来调查galsulfase和AE之间的关联.
- 专注于AE发病时间,症状和临床意义.
主要成果:
- 在15个器官系统中确定了72个特定的不良事件,包括呼吸道和感染性疾病.
- 观察到的中位数AE发病时间为1471天,其中超过一半发生在治疗的前5年内.
- 检测到以前未报告的泌尿器官不良事件,如膜性淋巴结膜炎和性综合征.
结论:
- 这项研究提供了关于galsulfase安全概况的真实证据,突出了新的AE的出现.
- 鉴定以前未报告的泌尿器官不良事件需要进一步调查.
- 加强药物监测对于确保患者安全和优化galsulfase治疗疗效至关重要.
更多相关视频
10:16In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
8.1K
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
8.3K
相关概念视频
01:19Pharmacovigilance
797
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
797
01:25Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
01:17Assessment of the Gastrointestinal System I: Subjective Data
160
Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
160